Comstock/Comstock/Getty Images
Recombinant DNA (rDNA) technology, pioneered in the early 1970s by scientists such as Dr. Stanley Cohen and Dr. Herbert Boyer, revolutionized the biotechnology industry. By isolating specific DNA fragments, splicing them with other sequences, and inserting the hybrid material into host organisms like bacteria, researchers can now produce proteins on a large scale with precision and consistency.
Proteins engineered through rDNA have become essential therapeutics. For example, insulin, once extracted from animal pancreases, is now manufactured in genetically engineered bacteria, drastically reducing cost and ensuring a steady supply. Human growth hormone and other recombinant proteins are similarly produced, offering patients reliable and affordable options.
Traditional hepatitis B vaccines relied on attenuated or inactivated viruses. Modern rDNA‑based vaccines use purified viral proteins—noninfectious and free from whole virus particles—eliminating the risk of infection. This approach also bypasses the need for egg‑derived manufacturing, allowing production of influenza vaccines that are safe for individuals with egg allergies.
Large‑scale production of proteins is critical for biochemical studies. Purifying a low‑abundance protein from animal tissue can be time‑consuming and yield insufficient quantities. rDNA methods enable the transfer of the target gene into fast‑growing bacteria, producing ample protein for purification, functional assays, and structural analyses with reduced time and effort.
Genetically engineered crops can incorporate bacterial proteins that confer pest resistance or herbicide tolerance. These traits, introduced via rDNA techniques, are claimed to improve yields and reduce chemical inputs. While supporters emphasize higher productivity and resource efficiency, critics raise concerns about ecological impact and long‑term health effects, arguing that the benefits may be overstated.
